ALT5 Sigma (NASDAQ:ALTS) Stock Price Down 2.2% – Here’s What Happened

ALT5 Sigma Corporation (NASDAQ:ALTS) shares dropped 2.2% during trading on Thursday . The company traded as low as $1.29 and last traded at $1.32. Approximately 1,152,010 shares were traded during trading, a decline of 43% from the average daily volume of 2,021,641 shares. The stock had previously closed at $1.35.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of ALT5 Sigma in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

ALT5 Sigma Trading Down 6.8%

The company has a quick ratio of 0.79, a current ratio of 0.79 and a debt-to-equity ratio of 0.01. The firm’s 50 day simple moving average is $1.63 and its 200 day simple moving average is $1.99.

ALT5 Sigma (NASDAQ:ALTS) last posted its earnings results on Monday, January 12th. The company reported $0.29 EPS for the quarter. ALT5 Sigma had a return on equity of 8.60% and a net margin of 133.06%.The firm had revenue of $7.58 million for the quarter.

Institutional Trading of ALT5 Sigma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Profund Advisors LLC acquired a new position in shares of ALT5 Sigma during the third quarter valued at approximately $28,000. Arete Wealth Advisors LLC bought a new position in ALT5 Sigma during the 3rd quarter valued at $28,000. Victory Capital Management Inc. acquired a new position in shares of ALT5 Sigma during the 3rd quarter valued at $33,000. First Citizens Bank & Trust Co. bought a new stake in shares of ALT5 Sigma in the 3rd quarter worth $35,000. Finally, Lantern Wealth Advisors LLC bought a new stake in shares of ALT5 Sigma in the 3rd quarter worth $36,000. 6.27% of the stock is currently owned by institutional investors.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.